Back
Protagonist Therapeutics Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Buy
66
PTGX
Protagonist Therapeutics
Last Price:
34.63
Seasonality Move:
-0.18%
Buy
51
ALNY
Alnylam Pharmaceuticals
Last Price:
242.97
Seasonality Move:
20.36%
Buy
66
Protagonist Therapeutics (PTGX)
is a Buy
Is Protagonist Therapeutics a Buy, Sell or Hold?
- The current Protagonist Therapeutics [PTGX] share price is $34.65. The Score for PTGX is 66, which is 32% above its historic median score of 50, and infers lower risk than normal.
- PTGX is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Buy
51
Alnylam Pharmaceuticals (ALNY)
is a Buy
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $243.08. The Score for ALNY is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.
- ALNY is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
PTGX Stock Price Chart
What is Protagonist Therapeutics's stock price today?
-
The Protagonist Therapeutics share price today is $34.65
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and PTGX is experiencing slight buying pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $243.08
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing slight selling pressure.
PTGX Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.73 | Buy |
| Relative Strength Index (14 RSI): | 63.74 | Buy |
| Chaikin Money Flow: | 688414 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (29.74 - 33.96) | Buy |
| Bollinger Bands (100): | (26.54 - 31.64) | Buy |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 22.91 | Buy |
| Relative Strength Index (14 RSI): | 86.77 | Buy |
| Chaikin Money Flow: | -1210062 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (135.8 - 205.74) | Buy |
| Bollinger Bands (100): | (136.44 - 176.64) | Buy |
PTGX Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 32.28 | Buy |
| 20-day SMA: | 32.49 | Buy |
| 50-day SMA: | 29.74 | Buy |
| 200-day SMA: | 24.17 | Buy |
| 8-day EMA: | 32.66 | Buy |
| 20-day EMA: | 32.14 | Buy |
| 50-day EMA: | 30.61 | Buy |
| 200-day EMA: | 26.01 | Buy |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 209.44 | Buy |
| 20-day SMA: | 176.25 | Buy |
| 50-day SMA: | 159.62 | Buy |
| 200-day SMA: | 165.96 | Buy |
| 8-day EMA: | 218.01 | Buy |
| 20-day EMA: | 188.75 | Buy |
| 50-day EMA: | 168.9 | Buy |
| 200-day EMA: | 168.09 | Buy |
Protagonist Therapeutics Earnings Growth & PTGX Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.10 per share, an increase next quarter of $2.69 per share, an increase this year of $4.32 per share, and a decrease next year of $2.45 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.32 per share, a decrease next quarter of $0.12 per share, a decrease this year of $0.46 per share, and an increase next year of $1.83 per share.
Protagonist Therapeutics Technical Analysis
| Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||